Colchicine has been traditionally used for the treatment of gout. At presen
t there is no generally accepted alternative to colchicine for the treatmen
t of acute attacks or for the prevention of further attacks. The complex ac
tions of this substance, which are mainly attributable to its stabilising a
ction on the cytoskeleton and cell membranes, and its special pattern of di
stribution form the basis for the results presented here regarding the prop
hylactic or therapeutic actions of colchicine in a whole range of other dis
eases. This is all the more significant in that in several instances it con
cerns diseases that have so far been unsatisfactorily controlled by other t
reatments. Because of its astonishing absence of side effects, some authors
consider that low dose colchicine may be considered as an alternative to p
revious therapies or even a means of first choice. It is therefor incorrect
to think that medical research has shown little interest in this long-know
n potential and has not sought to confirm promising options by means of con
trolled studies. Fibrotic and inflammatory systemic diseases and those in w
hich leucocytic chemotaxis play a role seem to be particularly predestined
for this.